Skip to main content

Table 5 Selected cases of aberrant PK or target expression likely affecting administered therapies

From: The impact of pharmacokinetic gene profiles across human cancers

Ctype Patient Primary regimen Additional therapy Age Stage Grade Detailsa Target c Metabolism Transport
BRCA TCGA-E2-A1LB Cyclo-phosphamide Paclitaxel Doxorubicin Anti-Hormoneb Trastuzumab 41 2 ER-   AKR1A1(3.01) - Dox ABCC2(4.77) - Pac
BRCA TCGA-E2-A158 43 2 ER- MAP2(−3.56) - Pac MAP4(− 3.29) - Pac   ABCC1(2.27) - Dox
BRCA TCGA-E2-A14V Lapatinib 53 2 ER+ EGFR(−4.65) - Lap CYP2C8(2.2) - Pac  
BRCA TCGA-AO-A0J3 Fluorouracil Methotrexate 67 2 ER+ MAP4(−3.11) - Pac   ABCC5(2.21) - 5FU,Meth FOLR1(− 3.42) - Meth
BRCA TCGA-BH-A0BA 51 3 ER+   NQO1(3.22) - Dox ABCC2(3.09) - Pac
BRCA TCGA-AO-A0JE Trastuzumab 53 3 ER-Margin+    ABCC1(2.73) - Pac, Dox ABCC2(3.86) - Pac, Dox
OV TCGA-09-0367 Carboplatin Doc/Paclitaxel Gemcitabine 67 3 3 LI + TRD+ MAP2(−3.66) - Pac MAP4(−3.96) - Pac NT5C(3.78) - Gem SLC31A1(−2.67) - Car
OV TCGA-23-1123 Doxorubicin 59 3 3 LI + TRD+   NR1I2(3.42) - Pac RALBP1(4.17) - Car,Dox
OV TCGA-24-1558 Doxorubicin 73 3 3 TRD+ MAP2(−4.71) - Pac,Doc   ABCC1(6.49) - Gem,Dox AABCC10(2.66) - Gem,Dox
OV TCGA-30-1860 Doxorubicin 58 3 3 TRD+ TOP2B(−4.39) - Pac,Dox MAP2(− 5.04) - Pac,Dox   
OV TCGA-61-1724 Doxorubicin Gemcitabine 47 3 3 LI+ MAP2(−4.57) - Doc DCTD(4.46) - Gem  
OV TCGA-61-1741 Tamoxifen 76 3 3 TRD+   CYP2C8(3.19) - Pac,Tam NR1I2(3.94) - Pac,Tam SLC31A1(−3.21) - Car
KIRC TCGA-CJ-4638 Gemcitabine Fluorouracil Bevacizumab 46 4 4   NT5C(3.84) UPB1(3.87) DPYS(2.33) - Gem,5FU  
LUAD TCGA-50-5072 Doc/Paclitaxel Carbo/Cisplatin   74 3 reformed smoker    ABCC2(5.12) - Doc,Pac
UCEC TCGA-AP-A052 Carboplatin Paclitaxel Gemcitabine 59 4 3   CMPK1(−4.12) - Gem NR1I2(3.92) - Pac  
UCEC TCGA-AP-A05D   67 3 3   MAPT(−3.05) - Pac TUBB1 (−2.43) - Pac   SLC31A1(− 3.7) - Carb
UCEC TCGA-AP-A0LI   67 3 3   MAP2(−5.57) - Pac MAPT(−2.21) - Pac   SLC31A1(−4.11) - Carb
UCEC TCGA-AX-A0IS Gemcitabine Brivanib 52 1 2   MAP2(−3.09) - Pac MAP4(− 3.27) - Pac DCTD(3.49) - Gem  
UCEC TCGA-AX-A1CR   70 2 3    NR1I2(3.18) - Pac SLC31A1(−5.04) - Carb
UCEC TCGA-BS-A0TE Doxorubicin Topotecan 35 4 3    AKR1C3(4.88) NQO1(3.68) NR2I1 (2.76) - Dox,Pac ABCC2(5.22) - Top
HNSC TCGA-CR-7404 Carboplatin Paclitaxel Cepecitabine Cetuximab 53 1 never smoker MAP2(−3.86) - Pac   ABCC5(5.08) - Cap
HNSC TCGA-DQ-7589 Docetaxel Fluorouracil 70 1 reformed smoker    ABCC1(5.83) - Doc,5FU,Pac ABCC5(4,74) - Coc,5FU,Pac
LUSC TCGA-46-6026 Doc/Pacletaxel Gemcitabine Paraplatin 81 2 reformed smoker CMPK1(−3.05) - Gem CYP2C8(3.02) - Pac NR1I2(3.86) - Pac  
LUSC TCGA-94-7033 Cisplatin 73 1 reformed smoker MAP4(−4.71) - Doc   SLC31A1(−3.26) - Cis
  1. aSpecific details for each case: ER, estrogen receptor; Margin, presence of tumor cells in surgical margins; TRD, rumor residual disease; LI, lymphatic invasion
  2. bAnti-hormone therapies; three received anastrazole, one tamoxifen
  3. cWhen multiple targets are lowly expressed, representatives are shown for brevity
  4. Target or PK genes of drugs for the administered regimen that exhibit differences from normal-tissue expression levels are shown with their Z-scores. After the Z-score, we indicate which administered therapy is directly affected by the expression change using abbreviated names